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Abstract: Acute liver failure is a rare hepatic emergent situation that
affects primarily young people and has often a catastrophic or even
fatal outcome. Definition of acute liver failure has not reached a uni-
versal consensus and the interval between the appearance of jaundice
and hepatic encephalopathy for the establishment of the acute failure is
a matter of debate. Among the wide variety of causes, acetaminophen
intoxication in western societies and viral hepatitis in the developing
countries rank at the top of the etiology list. Identification of the
clinical appearance and initial management for the stabilization of the
patient are of vital significance. Further advanced therapies, that
require intensive care unit, should be offered. The hallmark of treat-
ment for selected patients can be orthotopic liver transplantation.
Apart from well-established treatments, novel therapies like hepatocyte
or stem cell transplantation, additional new therapeutic strategies
targeting acetaminophen intoxication and/or hepatic encephalopathy
are mainly experimental, and some of them do not belong, yet, to
clinical practice. For clinicians, it is substantial to have the alertness to
timely identify the patient and transfer them to a specialized center,
where more treatment opportunities are available.
Key Words: acute liver failure, emergency room, liver trans-
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L iver failure can be classified into 3 forms: acute liverfailure (ALF) occurring within 48 hours to several days
and accompanied by numerous complications including
infection, coagulopathy, and encephalopathy; acute-on-
chronic liver failure (ACLF), with underlying chronic liver
disease resulting in rapid progression of liver disease and
displaying as additional jaundice and ascites; and chronic
liver failure (CLF) remaining over a course of several
months or years with chronic liver diseases.1 Of these,
ACLF and CLF appear frequently. The mortality rate of
them ranges from 40% to 80%.2
ALF is generally considered to be a rare pathology.3–5
However, it has detrimental consequences, which can often
lead to multiorgan failure or even to death, if not promptly
recognized and adequately treated. Orthotopic liver trans-
plantation (OLT) remains the only effective therapy for
critical patients.6,7 In the majority of cases, ALF affects
young patients, without known preexisting liver disease.
Very limited exceptions include reactivation of hepatitis B
virus (HBV), autoimmune hepatitis (AIH) as well as
Wilson’s disease (WD).6,8,9
Relative data indicate that up to 30% of patients with
chronic hepatitis B experience HBV reactivation each year,
and up to 8% of patients develop severe acute exacerbation
and may progress to ACLF;10,11 flare-ups of chronic hepatitis
B can progress to ACLF with high short-term mortality.11,12
Etiology is quite heterogeneous and encompasses a wide
variety of possible causative factors (Table 1), depending mainly
on geographical distribution; ALF varies according to the etiol-
ogy and center responsible for patient management.13 The most
common of them consist of toxins and drug-induced liver injury
(DILI), primarily in western, industrialized societies, as well as
viral hepatitis in the rest of the world.6,14 In ALF, the liver
synthetic ability is severely impaired, due to a massive cellular
necrosis of hepatocytes. The clinical manifestation includes the
presence of rapid progression of hepatic encephalopathy (HE),
precedent by jaundice and biochemical evidence of liver injury as
well as ascites and coagulation abnormalities of any degree.1
Coagulopathy is typically characterized by a spontaneous ele-
vation of the international normalized ratio (INR) of ≥1.5 (or
prothrombin time >15 s).7,14,15 Over the last years, advances in
the emergency transplantation as well as in critical care therapy
have significantly contributed to an amelioration of survival.7
DEFINITIONS
Trey and Davidson first introduced the term “fulminant
liver failure” almost 50 years ago. The original definition
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described a “potentially reversible condition, the consequence
of severe liver injury, with an onset of encephalopathy within
8 weeks of the first symptoms’ appearance in the absence of
preexisting liver disease.”16 Since then, a plethora of different
definitions have been suggested (Fig. 1), depending primarily
on the elapse of time from the start of disease and onset of
HE.5,7,17–19 O’Grady et al,20 for instance, proposed a further
subgrouping of ALF; they introduced the term “hyperacute
liver failure” for patients with a hebdomadal interval between
onset of jaundice and HE. A greater interval ranging from 8
to 28 days was labeled as ALF, whereas the term “subacute
liver failure” was used for an even greater interval up to
72 days. Bernuau et al21 proposed another classification to
fulminant—subfulminant, whereas the Japanese system,
represented mainly by Mochida et al,22 uses a distinction
between fulminant (up to 8 weeks, subdivided to acute,
subacute) and late onset with acceptable appearance of HE
after jaundice up to 24 weeks. Wlodzimirow et al23 have
performed a systematic review of the literature accessible to
them with regard to ALF definitions, and, surprisingly, 81
different studies used 41 different definitions, whereas 16
studies did not define ALF precisely. As an impact,
comparability among studies and further analysis could be
substantially impeded. It is noteworthy to mention that,
contrary to expectations, a more fulminant course of ALF is
associated paradoxically with a better outcome in many
published studies,5,7,17,18 and, in the majority of such cases,
the etiology of the fulminant course is attributed to
acetaminophen intoxication.24
EPIDEMIOLOGY
ALF is a rare life-threatening disorder characterized by
rapid progression and death.25 As an impact of the
aforementioned discrepancy in the definition of ALF,
the actual incidence of the pathology is regarded to be
underdiagnosed.18,26,27 ALF is considered to be more
common in women than in men as well as in white indi-
viduals than in the rest of the races.8,14 The median age of
patients upon presentation is 38 years.14,28 The western
world has an estimated annual incidence of fewer than 10
cases per million individuals.7 A reported rough estimation
in the United States mentions about 2800 ALF cases per
year.18 The reduced causative viral incidence in the United
TABLE 1. Etiology of Acute Liver Failure
Categories Cause Hallmark/Comment
Autoimmune Autoimmune hepatitis Predominance in women
Drug induced Acetaminophen (paracetamol)
Various
Common, dosage dependent (Table 2)
Metabolic Galactosaemia
Hereditary fructose intolerance
Rey’s syndrome
Tyrosinaemia
Wilson’s disease
Young children with viral syndrome and salicylate intake
Older children; Coombs (−) hemolytic anemia, hypouricemia,
and a low alkaline phosphatase level with a high bilirubin level
Neoplastic Metastatic mammary carcinoma
Lymphoma
The most common representatives
Pregnancy related HELLP syndrome
Acute fatty liver
Toxemia
(Pre)eclampsia with liver infarction
Acute hepatic rupture
Abdominal, pain, vomiting, headache, thrombocytopenia, elevated
ALT/AST, hemolytic anemia, edema
Defects in fetal and maternal mitochondrial long-chain 3-hydroxyacyl
coenzyme A dehydrogenase
Rare
Toxic Amanita phalloides toxin
Bacillus cereus toxin
Carbon tetrachloride
Yellow phosphorus
Mushroom poisoning EU>USA
“Fried rice syndrome”
Extremely rare
Extremely rare
Vascular Budd-Chiari syndrome
Ischemic hepatitis (shock liver)
Right heart failure
Sinusoidal obstruction syndrome
Hepatic outflow obstruction
History of hypotension and ischemia must be prolonged
After chemotherapies, before bone marrow transplantation
Viral Hepatitis A virus
Hepatitis B±Delta virus
Hepatitis C
Herpes simplex virus
Human herpesvirus 6
Varicella zoster
Cytomegalovirus
Epstein-Barr
Adenovirus
Parvovirus
Hemorrhagic fever viruses
Coxsackie B virus
Other than hepatitis, viruses are rather rare or/and etiologically
controversial. Hepatitis C is extremely rare and in the setting of
other underlying hepatic diseases. Immunocompromised
patients are predisposed. Hepatitis E is more common in endemic
areas and mainly in pregnant women
Others Heatstroke
Rhabdomyolysis
Rare
Due to heatstroke or drugs
HELLP indicates hemolysis elevated liver enzymes with low platelets.
This table contains information adapted from references.9,14,17,19,43,44,60
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States as well as in the majority of Western Europe is
attributed to better public health precautions, such as better
sanitation and vaccinations. In the UK and in the USA, drug
overdosing and, especially acetaminophen (paracetamol) tox-
icity, followed by idiosyncratic pharmaceutical reactions are
known to be leading causative factors.7,18,19 On the contrary,
in the eastern developing countries, 3 viruses (hepatitis A, B,
and E) are responsible for about 95% of the total ALF cases.7
Hospital survival has been dramatically increased during the
last decades in the United States and United Kingdom. This
positive evolvement has been interpreted through a manifold
improvement of early diagnosis, intense care unit (ICU) uti-
lization, and the opportunity of emergent liver trans-
plantations. The 3 leading causes of death in descending
frequency include multiorgan failure, liver failure, and sepsis.29
ETIOLOGY
The spectrum of ALF includes a plethora of different
etiological factors. A fundamental and practical classi-
fication (Table 1) of them is the distinction among
autoimmune, viral, metabolic, neoplastic, toxic, pregnancy-
related, pharmaceutical (drug induced), and vascular
ones.6,30 As it was previously clearly stated,5,18,19,31 there
exists a geographical distribution of certain ALF causes. In
cases, wherein a certain etiology cannot be elucidated, ALF
remains as indeterminate.3,30
AIH may also manifest as ACLF, with clinical char-
acteristics equal to ALF.28 It is thought that about 20% to
30% of the patients develop an acute course and to an even
lesser extent ALF, which might be induced by a triggering
agent including toxic injury, preceding viral infections, or
therapy with immune-modifying drugs.32 For the sub-
stantiation of diagnosis, apart from the related clinical
appearance, positive serum autoantibodies, remission under
glucocorticoids as well liver biopsy are required; liver biopsy
in an AIH-mediated ALF setting seems to be safe and
effective in diagnosing AIH, and corticosteroid therapy is
not associated with sepsis or high mortality and might
improve the outcome.33 Autoantibodies that can be found in
high titers in serum include, for instance, antinuclear anti-
body, antiactin antibody, anti–soluble liver antigen, and
quantitative immunoglobulins.17,31 Nevertheless, cases with
negative autoantibodies have been reported, wherein liver
histology determined the diagnosis.34 Advanced age and
high model of end-stage liver disease (MELD) score are
related with lethal outcome.32
Drug-induced ALF is uncommon, varies geo-
graphically, and remains a common cause of withdrawal of
drugs in both preclinical and clinical phases.4,35 Its main
representative constitutes acetaminophen hepatotoxicity.
The latter can be either intentional (suicidal attempt) or
even an inadvertent overdosing;36 acetaminophen overdose
is the leading cause of drug-induced ALF in several devel-
oped populations.37 In the United States, acetaminophen-
induced ALF represents about 46% of the overall ALF
cases, being followed by idiosyncratic DILI with a per-
centage of 11%.26
Of note, acetaminophen-associated ALF has been
linked to a better outcome in terms of highest rate of
spontaneous recovery as well as the lowest rate of death
compared with other causes.24 On the contrary, other eti-
ologies being implicated in ALF such as DILI or AIH have
a slower course and are associated with a 27% and 15%
possibility of spontaneous recovery, respectively.24
Moreover, antiepileptics and antimicrobial agents like
tuberculosis medicine, clavulanic acid, trimethoprim—
sulfamethoxazole as well as antimycotics are among the
most frequent drugs that are attributed to inducing ALF.38
A detailed list of the medications linked with the develop-
ment of ALF is presented in Table 2.
Metabolic causes of ALF include, among others, the
commonly implicated galactosemia, tyrosinemia, hereditary
fructose intolerance, and mitochondrial disorders (Reye’s
syndrome) in young children and WD in older children39–41
Specifically, Reye’s syndrome is most commonly seen in
children with viral infection and parallel intake of salicylate-
based medication.17 WD is a rare autosomal recessive
pathology of copper metabolism and thus requires special
attention. It is characterized by a systematic accumulation
of copper in the liver and other organs, due to a defect of a
gene responsible for copper transport and, especially a
P-type ATPase (ATP7B), which is found on chromosome
13q14.3.31 In the setting of ALF, the diagnosis can be really
challenging, as elevated copper in urine can be seen in ALF
regardless of etiology, and ceruloplasmin as a so-called
acute phase protein can range from low to normal or even
be elevated. For obtaining the diagnosis, liver biopsy is
regarded as gold standard.8 The presence of the Kayser-
Fleischer (KF) iris ring in half of the patients is thought to
be a relatively specific sign, albeit not pathognomonic, as
other pathologies also share this ocular lesion. KF rings are
observed in 95% of WD patients with neurological signs.42
For the establishment of KF diagnosis, a slit-lamp exami-
nation is mandatory, as, in most patients, copper accumu-
lation is not visible with the naked eye.43 In some cases, the
discrepancy of especially high bilirubin with normal alkaline
phosphatase might be helpful for diagnosis,44 although
objections of the validity have also been raised.31 Liver
transplantation is indicated for WD patients who present
either with ALF or with end-stage liver disease and severe
hepatic insufficiency as the first sign of WD. When WD-
related ALF deteriorates too quickly for conventional
treatment, living donor liver transplantation is an effective
therapeutic strategy.45
Neoplastic pathologies are well-documented causes of
ALF in the literature. The most common of them encom-
pass metastatic solid tumors, with the main representative
FIGURE 1. The 3 main well-established classifications for ALF. (i)
Williams-Schalm and O’Grady system (ii) Bernuau system, and (iii)
Mochida (Japanese) system. ALF indicates acute liver failure.
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ones being mammary adenocarcinoma as well as hemato-
logic malignancies, with the most frequent of them being
lymphomas.14,15,17,27,31,36
Obstetric complications like HELLP syndrome
(hemolysis elevated liver enzymes with low platelets), acute
fatty liver, toxemia, (pre)eclampsia with liver infarction, and
acute hepatic rupture constitute known underlying causes of
ALF in pregnant women.31,44 There is accumulating pieces
of evidence that (pre)eclampsia, HELLP as well as acute
fatty liver in pregnancy are expressions of the same entity
and hence share comparable clinical and pathogenetic ele-
ments such as platelet aggregation and vascular
phenomena.18 The management of HELLP syndrome–
related ALF must be multidisciplinary, and liver trans-
plantation, the only radical therapy for ALF, is worth
attempting.46
More or less known intoxications that lead potentially
to ALF include Amanita phalloides toxin,6,14,15,17,18,23
Bacillus cereus toxin, Carbon tetrachloride,17,18 and yellow
phosphorus.17 Poisoning by mushrooms such as Amanita
phalloides is mostly seen in the west coast of the United
States, central Europe as well as South Africa.19 Of note,
there exist 2 toxins, both of which are heat stable and thus
are not affected by cooking. The first one is called phallo-
toxin and damages the cell membranes of the intestinal
simple columnar epithelium, whereas the second one, α-
amanitin toxin (known also as amatoxin), is attributed to be
hepatotoxic and can even lead to death if doses reach 0.1 to
0.3 mg/kg.31,47 Before signs of liver failure are seen, gas-
trointestinal manifestation such as vomiting and watery
diarrhea (cholera like) commonly precede.6,14,17,31 The
reported mortality rate of mushroom-related ALF with
conventional therapy is 1.4% to 16.9%, and Escudié’s cri-
teria established the best performance with 100% accuracy
and the ability to recognize fatal cases of mushroom-
induced ALF.48 Likewise, King’s College Criteria (KCC)
established a good prognostic value for urgent liver trans-
plantation indication in Amanita phalloides–induced ALF.49
Vascular etiologies involve mainly Budd-Chiari syn-
drome (BCS), ischemic hepatitis (shock liver), right heart
failure as well as sinusoidal obstruction syndrome.17,31 BCS
is a rare pathology characterized by tender hepatomegaly
and acute hepatic vein thrombosis.19,36 It seems to be more
common in young female individuals.6 BCS-related ALF
dictates prompt diagnosis and management with anti-
coagulation in conjunction with cancer or thrombophilic
disorder evaluation; mortality might improve by trans-
jugular intrahepatic portosystemic shunt and/or OLT use.50
As far as viral hepatitis is concerned, hepatitis A and B
viruses rank as the most common viral causes whereas the
remaining pathogens such as hepatitis E, herpes simplex, or
even Epstein-Barr viruses are more likely to be found in
special categories of patients such as those who are immu-
nocompromised or during gestation. In HBV-ACLF
patients, some data indicate that human mesenchymal stem
cell transplantation might significantly decrease the mor-
tality rate, without raising the incidence of severe
complications.51 Hepatitis C virus can only very rarely lead
to ALF.8,19,36,52 Other known viruses that are implicated in
ALF are cytomegalovirus, varicella zoster, adenoviruses,
and parvovirus B19.36,53 By evaluating the dynamicity of
MELD, MELD-sodium, ALF early dynamic model, chronic
liver failure (CLF)-consortium ACLF score, and KCC for
predicting outcome in viral-induced ALF, the ALF early
dynamic model achieves better than MELD,MELD-Na, and
CLF-C ACLF scores and KCC for predicting outcome in
viral hepatitis-induced ALF.54
Other infrequent reported causes of ALF might be heat
stroke, particularly in military personnel, athletes, or
laborers requiring urgent OLT7,14,18,44,55,56 or even rhab-
domyolysis, for example, medicament associated.14
CLINICAL PRESENTATION AT EMERGENCY
ROOM
At early presentation, nonspecific symptoms are present
but could progress to complications, including cerebral edema
(CE), infections, coagulopathy, cardiopulmonary as well as
renal failure, and acid-base and/or metabolic disturbances.25
Upon arrival of a patient at the emergency room, it is
TABLE 2. Medications Being Linked With Acute Liver Failure26,30,60
Categories Substance
Antiallergic agents Diphenhydramine, loratadine, zafirlukast
Anesthetics Halothane, isoflurane
Antiepileptics Carbamazepine, lamotrigine, phenyntoin, valproate
Antibiotics Amoxicillin-clavulanate, ciprofloxacin, clarithromycin, levaquin, nicotinic acid, nitrofurantoin,
ofloxacin, trimethoprim, sulfonamides, telithromycin, tetracycline
Antidepressants Bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, venlafaxine
Antifungals Itraconazole, ketaconazole, terbinafine
Antineoplastic-immunosuppresive
agents
Azathioprine, cytoxane, dactinomycin, etoposide, methotrexate tamoxifen
Antipsychotics (neuroleptics) Quitiapine
Αntiretrovirals Didanosine, efavirenz
Antituberculosis Dapsone, isoniazid, rifampicin, pyrazinamide
Biological agents Gemtuzumab, ipilimumab
Cardiovascular Amiodarone, diltiazem, labetalol, lisinopril, valsartan
Herbal or dietary products Chaparral ,Germander, Jin Bu Huan, green tea extract, usnic acid, ephedra, multi-ingredient
products, for example, for weight loss
Nonsteroidal anti-inflammatory drugs Diclofenac, etodolac, indomethacin, naproxen
Hypolipidemic agents Atorvastatin, cerivastatin, ezetimibe, fluvastatin, pravastatin, simvastatin
Tyrosine kinase receptor inhibitors Imatinib, nilotinib, ponatinib
Various Allopurinol, carbon tetrachloride, cocaine, disulfiram, flutamide, metfomin,
Methylenedioxymetamphetamine (MDMA*: “Ecstasy”), phenprocoumon, tolcapone,
troglitazone
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substantial for the clinician to keep in mind that every alter-
ation of mental status combined with prolongation of INR/
coagulation abnormalities and jaundice should be suspected of
ALF. Further complaints and signs include fever, anorexia,
fatigue, abdominal pain, bleeding, and hemodynamic insta-
bility. Equally of great significance is to distinguish between
decompensated liver cirrhosis and new first diagnosed mani-
festation of ALF. Particularly helpful is the medical history of
the patient with regard to known family liver diseases, pre-
disposing factors for viral hepatitis (eg, polytoxicomania,
travel, sexual history), eating habits, and intake of medications
(also nonprescribed). During the clinical examination, corre-
sponding signs could be identified that are suggestive of
chronic liver disease (eg, cachectic patient with clubbing-leu-
conychia, gynecomastia, spider angiomas, and advanced
ascites with prominent abdominal wall veins as well as varying
hepatosplenomegaly). Herpetic skin lesions, tattoos as well as
possible needle tracks should also be investigated on the skin.
Eye examination should rule out or confirm KF rings, which
indicate corneal copper deposition in WD.31,57 It is important
to note, however, that KF rings are not specific to WD alone,
because they can also be observed in patients with other
chronic cholestatic disorders such as children with neonatal
cholestasis or primary biliary cholangitis.42,43 Moreover, ALF
can be easily misdiagnosed, especially if the clinical course is
quick enough and has hallmarks of only neuropsychiatric
manifestations such as confusion and agitation with barely
seen jaundice. In addition, in subacute cases, a misleading
diagnosis of chronic liver disease could be made, as portal
hypertension and ascites with nodular liver can be seen.5,7
About one-third of ALF patients may be admitted to the
emergency department with ascites, and 17.7% will also pres-
ent a spontaneous bacterial peritonitis.14 ALF leads to a syn-
drome with systemic manifestations (Fig. 2) characterized by
some or even all of the following clinical hallmarks: metabolic
disturbance with accompanying lactic acidosis, oliguria with
acute renal injury, blood hypotension, acute lung injury/acute
respiratory distress syndrome (ARDS), sepsis with possible
systemic inflammatory response syndrome, hypoglycemia, and
coagulopathy with clotting or bleeding tendency.30,44,58 About
60% of the patients with ALF fulfill the criteria for systemic
inflammatory response syndrome,59 regardless of whether a
bacterial etiology is found or not. Thirty percent of ALF
patients develop the aforementioned ARDS or acute lung
injury.52 Critically ill patients are prone to be complicated with
HE, CE, and intracranial hypertension (ICH).3,6,31,36,60,61
These serious complications account for 65% of the patients
with third-grade HE and 75% of those with fourth-grade
HE.62
As far as acetaminophen intoxication is concerned, the
recognition of ALF is usually plausible, as the history taking
of the patient and clinical course are rather typical. Patients
FIGURE 2. Clinical (extra) hepatic hallmarks of acute liver failure. AKI indicates acute kidney injury; ALI, acute lung injury; ARDS,
adult respiratory distress syndrome; ICH, intracranial hypertension; SIRS, systemic inflammatory response syndrome; UGI, upper
gastrointestinal; WBC, white blood cells.
J Clin Gastroenterol  Volume 53, Number 2, February 2019 Acute Liver Failure: From Textbook to Emergency Room
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. www.jcge.com | 93
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
are admitted to hospital and claim the intake of the drug in
suicidal attempt or accidental overconsumption. In the first
case, a great increase of transaminases (up to several 100
fold) within the first 3 days is to be expected. Acute kidney
injury (AKI), coagulopathy, HE, and acidosis are seen in
the next stages, and patients frequently die due to sepsis and
multiorgan failure. In the second case of accidental intox-
ication, patients present often with unconsciousness,
hyperthermia, hypotension, AKI, coagulopathy, jaundice,
and accompanying hypoglycemia. Patients with claimed
accidental overdosing have commonly a history of alcohol
addiction and take multiple pain relievers, not rarely 2 dif-
ferent acetaminophen preparations.14 Moreover, acetamin-
ophen-related ALF seems to be more frequent and severe
among women.63 Remarkably, pancreatitis could also be a
complication of ALF in acetaminophen toxicity.7,8
In a recent relevant US study, survival was evaluated
with or without OLT among ALF patients. Remarkably,
acetaminophen category patients, although representing
only 22% of the totally listed patients, developed a greater
illness severity with higher coma grades and greater ven-
tilator and vasopressor or renal replacement therapy sup-
port necessity, whereas a minority of them required a graft,
compared with autoimmune, DILI, and HBV-related ALF
patients. Thus, acetaminophen intoxication outcome
evolves rapidly, resulting either in spontaneous survival
without OLT or in death.24
Noteworthy is also the category of WD patients, on
grounds that they have a very typical clinical presentation,
albeit very rare; patients are admitted with HE, they are at
their later puberty, and present icteric due to hemolysis and
consequently exceptionally elevated indirect bilirubin as well
as established liver cirrhosis.5 Serum ceruloplasmin is typi-
cally low (mostly of cases <20mg/dL) but can be normal in
up to 15% of ALF cases. Notably, ceruloplasmin can also be
low in other causes of ALF. Moreover, serum zinc is low in
WD-induced ALF, thereby it appearing to be a novel
parameter for diagnosis correlated with WD severity.64
Likewise, a ratio of alkaline phosphatase to total bilirubin
<4 and an AST to ALT ratio > 2.2 are regarded as highly
sensitive and specific predictors of fulminant WD.65 WD
along with hepatitis B and AIH consist of the 3 exclusions,
wherein an underlying preexisting hepatic condition should
be ruled out before ALF is diagnosed.14
A history of wild mushrooms’ ingestion and onset in
about 12 hours of watery diarrhea, mimicking cholera
voluminous “rice-water stool,” is suggestive of Amanita
phalloides–related ALF.14,30,49
INITIAL MANAGEMENT
Once a patient arrives at the emergency room, the
suspicion of a possible ALF, alerts the clinician for a cas-
cade of related history-based questions as well as diagnostic
measures.66 As ALF patients frequently present with cir-
culatory instability or they are even in a state of shock state,
cardiovascular support emerges as the initial step to restore
and maintain intravascular volume and metabolic balance,
thus avoiding further deterioration of liver function and
multiple organ damage. This crucial step embodies the
administration of adequate fluid resuscitation to preserve
sufficient perfusion for all tissues and correction of electro-
lyte disturbances (especially hypokalemia and hypo-
phosphatemia) and acid-base disorders (mixed respiratory
and metabolic alkalosis most commonly, unless lactic
acidosis complicates the metabolic state).30,60 In severe
cases, the implication of vasoconstrictors, and particularly
norepinephrine, could be regarded as an early life-saving
intervention.66 In addition, the prevention of stress ulcers by
administration of proton pump inhibitors and regular
monitoring of blood glucose levels (hypoglycemia indicates
poor prognosis in ALF) stand as supplementary measures in
the management of ALF.67,68 As regards the increased risk
of infections, which lead even to sepsis, although the usage
of broad-spectrum antibiotics is not generally recom-
mended, the administration of empiric antibiotic therapy
can be considered in a clinical setting of persistent hypo-
tension or worsening encephalopathy for the prevention of
infectious complications and further deterioration.69–71 An
echocardiography can help the distinction between circu-
latory insufficiency and cardiogenic shock.72 Vitamin K
serves as an additional measure that could correct or
exclude any nutritional deficits. The latter could contribute
to the prolonged PT/increased INR.73 Moreover, although
N-acetylcysteine constitutes the first choice of medication in
cases of acetaminophen overdose, it is also regarded as an
antioxidant agent and vasodilator offering benefit in non–
acetaminophen-associated hepatotoxicity leading to
ALF.74,75 The recurrent monitoring of coagulation and
neurological status is substantial in any patient with estab-
lished liver dysfunction, as the progression to ALF sig-
nificantly affects the final prognosis.
It is important to note that the mentioned rapid
restoration of intravascular volume with intravenous fluids
and electrolyte and acid-base disturbance corrections, as
well as other cause-specific interventions can be adminis-
tered in non–intensive care unit settings, thereby diminishing
delay.76
There are some specific measures that target etiological
factors and can be considered as lifesaving under certain
circumstances. In cases of pregnancy complicated with
AFLP or HELLP, the decision for prompt delivery is
recommended.77,78 In addition, acute presentation of HBV
infection with impaired hepatic function should be treated
with a nucleos(t)ide analog79 like tenofovir or entecavir.
Furthermore, it is worthy to be emphasized that nucleos(t)
ide analog treatment should be considered in each patient
with severe acute hepatitis B. This approach can potentially
prevent the development of ALF, thereby decreasing mor-
tality. Starting such a treatment in patients with established
ALF is most likely to be too late. Relevant studies support
and encourage this principle in terms of safety as well as of
efficacy.80–82
Once BCS diagnosis is established, the timely initiation
of anticoagulation in therapeutic doses and—when available
—angioplasty can improve the patient’s prognosis.50
Finally, in mushroom-induced ALF, it is crucial to apply all
dispensable measures, including prompt administration of
silibinin (the major active constituent of silymarin), gastric
lavage and activated charcoal, and enough diuresis on top of
proper hydration. Nevertheless, it has to be mentioned that
gastric lavage as fundamental supportive therapy for
mushroom poisoning has been questioned by some
authors.83,84
Another antibiotic usually used in practice is penicillin
G and works well in various settings; it competes with
amatoxin for binding sites on serum proteins and prevents
hepatocyte uptake;85 it helps to prevent the HE progression,
and the recommended dosage is 40,000,000 U/d for adults
and 1,000,000 U/d for children.86 Likewise, ALF induced by
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amatoxin-containing mushroom can also be treated by
penicillin G, silibinin, and plasma exchange combination
regimen.87
In specialized centers, further therapeutic modalities
for critical ALF patients include the application of artificial
liver support devices such as MARS (molecular adsorbent
recirculating system) or fractionated plasma separation and
adsorption.57,88–90 In general, MARS and fractionated
plasma separation and adsorption might have the potential
to increase the probability of short-term survival of patients
with ALF or ACLF and can be introduced for bridging to
liver transplantation;91 MARS therapy seems to successfully
replace hepatic function in ALF, thereby allowing time for
spontaneous recovery or transplantation.92 Both
approaches, however, are not appropriate for long-term
therapy;91 MARS in patients with ALF failed to show a
survival improvement in the overall study cohort.93 More-
over, therapeutic plasma exchange seems to provide a sur-
vival benefit in nontransplanted patients with ALF.93 This
approach seems to significantly improve survival above that
seen with standard medical care, although the survival
benefit is inferior to that seen with transplantation;94 it is
introduced early in ALF patients with an expected poor
prognosis without transplantation but who have clear
medical or psychiatric contraindications to surgery,69 and its
use is associated with a significant cardiovascular condition
improvement in patients with worsening cardiovascular
failure and vasopressor requirement while they are wai-
tlisted for liver transplantation.93
It is considered substantial for the clinician to promptly
calculate the mentioned score of MELD and KCC, while
the timely referral to a liver transplantation center is decisive
for the prognosis of ALF.4,15 Nevertheless, during the last
years, KCC have been disputed, as they have been shown to
have limitations; they were developed in 1989 once OLT
was not that widely established, and they are attributed to
have poorer sensitivity and negative predictive value,95,96
compared with other newer models.97,98 Worth mentioning
is a recently developed multivariable logistic regression
model of the American ALF Study Group (ALFSG). The
authors have included prospectively 1974 ALF patients in
order to predict transplant-free survival and claimed this
model to be superior to both the KCC and MELD score.
Further large-scale studies are, however, warranted in order
to confirm its applicability.99
Early referral of selected ALF patients to a specialized
center with transplantation capability will permit a better
depicting of patients and distinguish between the ones who
may profit from an OLT (and respectively stabilize and pre-
pare them) and the ones who have a better chance for spon-
taneous recovery without undergoing a transplantation. This
prediction of ALF cases is not always plausible and can be
challenging also for experienced clinicians, as not all acute
hepatopathies lead always to ALF. It is thus advisable that all
patients with poor general condition upon first presentation
and those with proven etiologies that are associated with a
more fulminant course such as acetaminophen intoxication
should directly be referred to a center with transplantation
capability and receive immediate specific as well as supportive
therapy. Moreover, the relatively new practical guidelines69
from the European Association for the Study of the Liver
(EASL) include concrete suggested criteria for referral of such
candidates; etiologies are classified to paracetamol (also
hyperacute causality) and nonparacetamol ones. The former
patients should meet the following criteria: hypoglycemia,
elevated lactate unresponsive to fluid resuscitation, altered
level of consciousness, oliguria and/or elevated creatinine,
prolongation of INR> 3.0 on the second day or > 4.0 the next
days and arterial pH <7.30 (or HCO3< 18). Regarding non-
paracetamol ALF causes, required criteria include INR > 1.8
and arterial pH as well as HCO3 limits as previously stated. In
addition, bilirubin should reach a value > 300 μmol/L
(17.6mg/dL), and patients should present with oliguria/renal
failure (or sodium <130mmol/L), encephalopathy, hypo-
glycemia, or metabolic acidosis and appear to have a
shrinking liver size (Table 3).
INTENSIVE CARE UNIT TREATMENT
ICU management focuses on the clinical presentation,
identification, and management of the several complications
observed in ALF patients.100 Outcomes are better with early
detection and prompt initiation of etiology-specific therapy,
intensive care protocols, and OLT.
The mentioned ICH and CE consist of 2 of the chal-
lenging complications that develop in critical ALF patients
and that ICU clinicians are called to confront; ICH and CE
complicate about 75% to 80% of patients with ALF and
grade III or IV HE, and they remain prominent causes of
death.101 ICH is frequently preceded by CE and HE and is
well known to contribute to transtentorial herniation, which
can lead to death.28,57,100 Mechanisms that contribute to
ICH and CE include cytotoxicity due to osmotic effects of
ammonia, glutamine, other amino acids, and proin-
flammatory cytokines, as well as cerebral hyperemia and
vasogenic edema due to the blood-brain barrier disruption
with quick low molecular substance accumulation. Dys-
function of sodium-potassium adenosine triphosphatase
pump with loss of autoregulation of cerebral blood flow has
been implicated as a cause of hyperemia.7,57,100–102
There are classically described 4 grades of HE, the so-
called West Haven criteria:17,27,57,103 A variant of the
aforementioned criteria is the also known Parsons-Smith
scale (Table 4).19 As regards the management of HE,
sedating medications are generally contraindicated, as they
can mask a potential further progression of the condition.
Antipsychotic agents with a short half-life such as haloper-
idol can be given selectively to patients with great agitation.
Ammonia-focused treatment constitutes the basis of current
HE therapy in ALF setting.7,9,100
Once HE has advanced to grade 3, an intubation of the
airway with accompanying mechanical ventilation is
TABLE 3. Suggested Referral Criteria of ALF Patients by EASL69
Nonparacetamol
Etiology
Paracetamol and Hyperacute
Etiology
pH< 7.30 or HC03< 18 pH< 7.30 or HC03< 18
INR> 1.8 INR > 3.0 (second day) or
> 4.0 thereafter
Oliguria/renal failure or sodium
<130mmol/L
Oliguria and/or elevated
creatinine
Encephalopathy, hypoglycemia,
or metabolic acidosis
Altered level of consciousness
Bilirubin > 300 μmol (17.6 mg/
dL)
Hypoglycemia
Shrinking liver size Elevated lactate unresponsive to
fluid resuscitation
ALF indicates acute liver failure; EASL, European Association for the
Study of the Liver; INR, international normalized ratio.
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appropriate;14,61,100 ICU admission with airway controlling
and CE decreasing by hypertonic saline, mannitol, hypo-
thermia, and sedation are commended as a bridge to liver
transplantation.100,104 Of note, the establishment of a pri-
mary prophylaxis should be considered in ICU patients with
gastrointestinal bleeding, so that an overt HE can be
avoided.105
Interestingly, there is a lot of debate in the literature
with regard to intracranial pressure (ICP) monitoring,
without, however, consensus. Its significance is theoretically
at least plausible, as the seamless monitoring could identify
early an ICH and allow a rapid and targeted therapy. There
are 2 basic categories of ICP monitoring, an invasive and a
noninvasive one. Although invasive methods are regarded
as more accurate and thus the so-called gold standard, their
usage is rather limited due to the possible complications and
the lack of significant evidence supporting a clear clinical
benefit for the patient. Infections along with intracranial
hemorrhage (bleeding accounts for up to 10% of ALF
patients) constitute the most reportable complications after
catheter insertion on grounds of the preexisting
coagulopathy.18,106,107 Several ALFSG, including the
American one, recommend the placement of ICP monitor-
ing in patients with high-grade HE.106 With regard to the
noninvasive modalities to monitor ICP belong among others
the transcranial Doppler, jugular bulb oximetry, serial CT
of the head, and pupillometry. The limitation of such non-
invasive diagnostic methods is the necessity for a baseline
imaging.100 Nevertheless, a recent retrospective study that
evaluated the accuracy of 3 noninvasive ultrasound-based
monitoring modalities, deduced that none of these were able
to detect reliably a concurrent ICP elevation, documented
with invasive monitoring.107
In this respect, cerebral perfusion pressure (CPP),
defined as the gradient between mean arterial pressure and
ICP plays a substantial role for the management of
CE.100,108 Particularly, ALF patients with CE have been
found to have a relatively better outcome when a low ICP
with simultaneous adequate CPP is maintained.100,108 On
the contrary, prolonged low values of CPP (< 50mmHg)
along with elevated ICP (> 40 mmHg) have been associated
with detrimental consequences in both neurological as well
as posttransplant terms.109
Patients with ALF often develop concomitant AKI, via
a number of pathogenic mechanisms such as renal hypo-
perfusion, direct drug-induced nephrotoxicity causing acute
tubular necrosis, or sepsis/systemic inflammatory response,
which contributes to increased morbidity and severe
prognosis.68 Moreover, ACLF patients display an AKI high
incidence correlated with 30-day and 90-day mortalities.110
The majority of critically ill ALF patients are admitted to
the ICU with certain volume depletion, often due to gas-
trointestinal bleeding, which contributes to prerenal kidney
injury. Fluid resuscitation should not be aggressive, as well
as the usage of vasopressors over fluids to maintain stable
blood pressure. Dopamine is superior to norepinephrine,
due to the advantage of the first on oxygen delivery in the
peripheral tissues.14,28,100 The early introduction to renal
replacement has been a modality that is being adapted by
several transplantation centers.7,14,28,57,100
Coagulopathy is also seen in ALF patients being hos-
pitalized in ICU. This is a consequence of massive hep-
atocellular necrosis, which affects the production of both
anticoagulation and procoagulation factors with further
increase of INR. Simultaneous thrombocytopenia can also
be found in patients with known multiorgan failure.9,28,57,100
Contrary to CLF, such patients develop a reduction of
factors II, V, VII, and X, whereas factor VIII is increased, as
a result of acute inflammation. It is believed that there is
overall a predisposition for hypercoagulation, which can
lead to deep vein thrombosis.100 It is important to note that,
despite a bleeding diathesis, clinically important bleeding is
infrequent in ALF patients; bleeding complications in ALF
patients are indicators of rather severe systemic inflamma-
tion than of coagulopathy and hence portend a poor
prognosis.111 Again, current well-described detailed
protocols112 are also utilized for the management of coa-
gulopathy before and following insertion of an ICP monitor.
Infections constitute a known complication of ALF.
Bacterial infections induce systemic inflammation that may
result in organ failure and ACLF through complex mech-
anisms leading to a high risk of short-term mortality;113
infection is one of the most fatal complications in ALF,
particularly when accompanied by multiorgan failure, with
a reported incidence of up to 90%;28,54 liver failure com-
plicating sepsis/septic shock has an important impact on
mortality in ICU patients;114 and streptococcal toxic shock
syndrome is complicated with acute liver and renal failure,
ARDS, and disseminated intravascular coagulation.115
Functional monocyte damage and consequent immune
paresis contribute to increased susceptibility for infections in
ALF.9,116 The most common infections include pneumonia,
urinary tract infection, and catheter-associated bloodstream
infection.57 The causative microbes are mainly bacteria with
slight predominance of Gram-negative bacilli over Gram-
positive cocci, whereas fungal infections occur rarely.28
Although no survival benefit has been demonstrated by the
use of antimicrobial prophylaxis, the current guidelines
suggest antibiotic coverage particularly in patients with
high-grade of HE (3/4) and definitely in those who are
intubated or require renal replacement therapy.100 A com-
bination of a beta lactam antibiotic (eg, piperacillin/tazo-
bactam or a carbapenem according to the local nosocomial-
resistant microbes) with vancomycin is recommended.28
Nevertheless, the spread of multidrug-resistant bacterial
infections nowadays has reduced the efficacy of usually used
antibiotics.117 Surveillance for infection with daily chest
x-ray and regular cultures of blood, tracheal aspirate, and
TABLE 4. Grading of Hepatic Encephalopathy (Modified Parsons-Smith scale)19
Grade Vigilance Neurology Glasgow Coma Scale
0 or subclinical Normal Only seen in neuropsychometric testing 15
1 Minor lack of awareness, shortened attention span Apraxia, tremor, incoordination 15
2 Lethargy, disorientation, personality change Ataxia, dysarthria, flapping tremor 11-15
3 Confusion, somnolence to semistupor, response to
stimuli
Ataxia, flapping tremor 8-11
4 Coma With or without decerebration < 8
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urine should be undertaken, whereas central lines should be
monitored periodically for signs of infection in order to be
removed or replaced, and their tips should be cultured as
well. Isolation of a potentially harmful microbe in cultures
should be followed by prompt modification of antibiotic
scheme. In case of deterioration of clinical presentation
without any laboratory finding or positive culture, an
enhancement of antibiotic treatment with the addition of
aminoglycoside or polymyxin E (also known as colistin) is
suggested. If the patient’s condition is refractory to the latter
change, the addition of antifungal coverage (eg, micafungin)
is reasonable.100
Hypoglycemia may also appear in the setting of ICU in
ALF patients. The diminished capability of liver for glu-
coneogenesis along with emesis and poor oral intake lead to
exhaustion of glycogen stores. Immediate therapy as soon as
hypoglycemia is recognized is recommended, as the neuro-
logical consequence might be detrimental. Blood glucose
levels should be monitored closely (at least 4 hourly) in
patients with severe liver failure. Severe liver injury–induced
hypoglycemia is one of the causes of hypoinsulinemic
hypoglycemia; hypoglycemia is improved by glucose infu-
sion, although the liver injury is not improved.118 A rea-
sonable blood glucose target is 6.0 to 10mmol/L (108 to
180 mg/dL), using hypertonic dextrose solutions if neces-
sary. Repeated low concentrations of dextrose-based intra-
venous solution of 5% to 10% should be avoided, because
they may cause a nondesired hyponatremia with the known
negative impact on brain edema.7,57,61
LIVER TRANSPLANTATION
Upon the arrival of liver transplant for ALF, the sur-
vival rate has improved considerably. Liver transplant for
ALF accounts for 8% to 10% of all transplant cases.7,60,119
The 1-year survival rates are 79% in Europe and 78% to 84%
in the United States and fall to 71% 4 years later.119
Remarkably, the survival of patients being transplanted due
to CLF appears to be higher than that of patients being
transplanted due to ALF. Postulated reasons for this include
the emergent setting of operation, the higher incidence of
immunologically mediated graft dysfunction as well as the
coexisting organ failure(s).120 Criteria, which should be met
in order for a patient to qualify for OLT, are the well-
described and above-mentioned KCC (Table 5).3,17,19,28,44
As regards acetaminophen hepatotoxicity, KCC criteria
have a strong positive predictive value for ICU-related
death without transplantation.3,44 Interestingly, living donor
liver transplantation can be introduced in ALF patients with
grade IV encephalopathy, with a success rate comparable to
that of non-ALF patients undergoing liver transplantation.121
Advances in medicine of critical care have significantly
enhanced the spontaneous survival in ALF patients from
15% to 40%.31 Among patients being listed for trans-
plantation, 37% will recover spontaneously without the need
for OLT, and it is estimated that as many as 20% of ALF
patients may be transplanted without actual necessity.31
NOVEL THERAPIES
Beyond the above-mentioned and well-established
therapies for ALF, there do exist some additional, less evi-
dence-based ones. Because of their experimental character,
they do not have a place, at least yet, in clinical application.
As regards N-acetylcysteine recommended in
acetaminophen-induced ALF, the narrow therapeutic win-
dow limits its administration. Therefore, novel therapeutic
strategies that can offer broadly protective effects against
ALF are warranted. In this respect, apart from mitochon-
drial oxidative stress, several other cellular processes,
including phase I/phase II metabolism, endoplasmic retic-
ulum stress, sterile inflammation, microcirculatory dys-
function, autophagy, and liver regeneration, are involved in
ALF pathogenesis, thereby offering novel targets for
developing effective therapeutic strategies against
acetaminophen-related ALF.37 For instance, autophagy is
activated in response to acetaminophen overdose in certain
liver zone areas, and autophagy pharmacological activation
protects against acetaminophen-related ALF.122 Moreover,
p53 demonstrates a protective role in regulating acetamin-
ophen metabolism and disposition, thereby offering a novel
therapeutic target for acetaminophen-induced ALF.123 The
gut microbial metabolite, 1-phenyl-1,2-propanedione, is also
involved in aceteminophen-induced rhythmic hepatotox-
icity, by depleting hepatic-significant antioxidant gluta-
thione, thereby signifying that gut microbiota might be an
additional target for decreasing acetaminophen-related
ALF.124
Human hepatocyte transplantation has been intro-
duced as an alternative to liver replacement for ALF. Spe-
cifically, one of the main indications for human hepatocyte
transplantation therapy is ALF125,126; human hepatocyte
transplantation has been actively perused as an alternative
to liver replacement for ALF.127 In this regard, 37 patients
with ALF have been treated with human hepatocytes for
drug-induced, viral, and obscure ALF. Ten of these patients
received intraportal hepatocyte infusions, with 2 making a
full recovery without the requirement of OLT, and 3 were
TABLE 5. King’s College Hospital Prognostic Criteria (Left) and UNOS Criteria (Right)44,58
Kings College Criteria
Nonparacetamol Hepatotoxicity Paracetamol Hepatotoxicity UNOS Criteria for Status 1 Listing
Prothrombin time > 100 s Arterial pH <7.30 (7.25 if given
N-acetyl cysteine)
Onset of encephalopathy of any degree 8 wk
after the acute liver failure onset
Prothrombin time > 100 s Any 3 of the following:
unfavorable etiology (seronegative or drug-
associated fulminant hepatic failure), Jaundice
> 7 d before encephalopathy, age <10 or > 40 y
prothrombin time > 50 s serum bilirubin
> 300mmol/L
Or all of the following: prothrombin
time > 100 s, creatinine
> 300mcmol/L, grade III
encephalopathy
Absence of preexisting liver disease
Life expectancy of <7 d and in the intensive
care unit requiring either mechanical
ventilation, renal dialysis, or with severe
coagulopathy (INR> 2.0)
INR indicates international normalized ratio.
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successfully bridged to transplantation.128–131 Recent data
indicate that domino hepatocyte transplantation, by using
livers that would not meet transplantation criteria, is one of
the available alternatives to treat ALF patients; it might be an
excellent strategy to increase cell supplies for hepatocyte
transplantation.132
Compared with solid organ transplantations, cell
transplantation advantages include the potential to treat
more patients with a substantially less invasive procedure,
and leaving the native organ in situ with regeneration
potential. Clinical hepatocyte transplantation safety and
short-term efficacy have been proven. However, present
challenges include a reduced cell source, decreased
cell viability following cryopreservation, and poor engraft-
ment of cells into the recipient liver with consequently a
limited lifespan.127,133,134 Therefore, alternative stem cell
sources including pluripotent stem cells, fibroblasts, hepatic
progenitor cells, amniotic epithelial cells, and mesenchymal
stem/stromal cells can be introduced to generate induced
hepatocyte-like cells, with each technique exhibiting
advantages and disadvantages. Mesenchymal stem/stromal
cells transplantation had beneficial effects, especially in
ACLF patients.1 However, long-term functionality of
transplanted hepatocyte-like cells and the potential carci-
nogenic risks of administering stem cells have yet to be
proven.127
Research has focused also on HE potential novel therapies,
as a substantial body of evidence has signified that inflammation
acts in concert with ammonia in HE pathogenesis, and inflam-
matory mediators have a significant role in modulating the
cerebral effect of ammonia. Relative novel and potential ther-
apeutic strategies include hypothermia, minocycline, non-
steroidal anti-inflammatory drugs, tumor necrosis factor-alpha
antagonists, and p38 inhibitors, which seem to ameliorate sys-
temic inflammation—neuroinflammation, improve or reverse
neuropsychiatric manifestations, and prevent the onset and
progression of HE in patients and/or animal models of ACLF.
These data point to the possible therapeutic utility of decreasing
inflammation in HE therapy, and translation of these exper-
imental data to the clinic may provide novel and promising
therapeutic approaches for patients with HE secondary to ALF
or chronic liver failure.135,136 In this regard, recent evidence
suggests the role of fecal microbiota transplantation in the
treatment of HE with promising results, although additional
research is needed.137 Moreover, as hepatic autophagy is an
essential mechanism for ammonia detoxification because of its
support of urea synthesis, its augmentation has the potential for
the treatment of both primary and secondary causes of
hyperammonemia.138
CONCLUSIONS
ALF still remains a rather rare but often fatal entity,
which requires high clinical suspicion and alertness. The
sooner a patient is identified with ALF, the sooner the
transfer to specialized centers with the capability of a high-
level multidisciplinary intensive care, and the more the
possibilities exist for a favorable outcome. Usage of the
aforementioned calculation tools along with EASL sug-
gested referral criteria69 could contribute to such a decision-
making.
CE with ICH and infections rank among the most
common causes of death in critical ALF patients. OLT is
offered as an option for selective patients and has overall
and remarkably improved ALF survival in the last decades.
The leading cause of ALF in the western societies is
drug-associated ALF and, particularly acetaminophen over-
dose, whereas, in the less developed societies, viral hepatitis
remains a significant causative burden. Beyond the well-
established treatments, future large-scale studies are war-
ranted for a further validation of modern experimental
therapies such as hepatocyte or stem cell transplantation and
novel therapeutic strategies targeting acetaminophen intox-
ication and/or HE before the current problems are overcome
and a consensus is achieved for a clinical appliance.
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